According to the National Cancer Institute (NCI) triple negative breast cancer is subtype of breast

The baseline cohort was retrieved from the SEER9 database and consisted of females diagnosed with breast cancer as a first primary cancer identified by diagnosis codes from the International Classification of Diseases for Oncology

An effective breast cancer treatment in some women can be traced to the root of the disease. Some of the most aggressive form of breast cancers are caused by a transmembrane receptor protein known as Human Epidermal Growth Factor Receptor 2 (HER2) which is a member of the HER family of receptor tyrosine kinase. Approximately 20,000 HER2 receptor are normally expressed on surface of healthy breast cell however, in about 25% of breast cancer cells the HER2 protein is overexpressed resulting in tumour cells with as many as over 2 million receptors present on their surface. This cancer is known as HER2 positive (HER2+). The effect of HER2 overexpression is an increase in receptor mediated intracellular signalling causing the cell

Throughout this event I learned what triple negative breast cancer is. Triple negative breast cancer is any breast cancer that does not express the genes for estrogen receptors, progesterone receptor or Her2/neu. I also learned that triple negative breast cancer tends to affect African-American women the most then any other race. I believe that this finding is important because if we know that triple negative breast cancer mostly

The field of breast cancer treatment is in continual flux, and to keep “abreast” (pardon the pun) of the latest updates, consider attending our educational evening seminars, where local care providers offer the most up-to-date information. And read all you can; breast cancer is often in the news. As a way to filter the truth from hype in mass media, I highly recommend

Luminal A is the subtype in which the breast cancer is ER and/or PR positive, and HER2 negative. Luminal B is the subtype in which the breast cancer is ER and/or PR positive, and either HER2 positive of negative. Basal like is the subtype in which breast cancer is ER and PR negative, while also being HER2 negative. HER2 is the subtype in which the breast cancer is ER and PR negative, while being HER2 positive. This is usually successfully treated with therapies that target the HER2 protein. Depending on the expression of the receptors, different treatments such as radiation, surgery for removal of cancer, chemotherapy, and hormonal therapy can be used.

First a look back: In October, many of us at the Coalition had the pleasure of attending the 3rd Annual Multidisciplinary Breast Cancer Seminar right here in Rochester. This event was developed and produced by Physicians and Laypersons Educational Associates of Greater Rochester New York (PLEA of GRNY) an organization founded by mother and son physicians, Dr. Ruby Belton and Dr. Douglas Belton Jr. PLEA of GRNY represents a union of multidisciplinary breast cancer care physicians, other medical caregivers, and laypeople. This seminar offered us a chance to learn about emerging trends in breast cancer treatment, as well as receive updates about current treatments. The multidisciplinary approach meant that physicians specializing in diagnostic radiology, surgical oncology, medical oncology, radiation oncology, plastic surgery and survivorship presented on topics about their specialty areas throughout the evening. It was a treat to have many of our well-known providers front and center at the dais or on the panel. We also heard from a lawyer who presented on the legal aspects of Governor Cuomo’s new

The epidermal growth factor receptor (EGFR) is the cell-surface receptor for extracellular protein ligands. EGFR family has four closely related receptor tyrosine kinases: EGFR (ErbB-1), HER2/c-neu, Her 3 and Her 4. Mutations affecting EGFR expression or activity could lead to cancer.

Several ongoing trials are addressing the intensification of adjuvant chemotherapy in TNBC patients, either through integration of novel agents into the adjuvant setting such as platinum, X, ixabepilone, or bevacizumab, or through introduction of maintenance therapy such as X (CIBOMA and SYSUCC-001) or bevacizumab (BEATRICE). Preliminary results of the CREATE-X (JBCRG-04) trial by the Japan Breast Cancer Research Group were presented at the 2015 San Antonio Breast Cancer Symposium (Toi, , et al.2016). The trial randomized 910 patients to observation versus 8 cycles of X therapy, and reported improved rates of 2-year DFS (87.3 vs. 80.5%; p = 0.001) and OS (96.2 vs. 93.9%; p = 0.086) with X. All of the observed benefit was driven by the improved outcome in the ER-

Design: This was a Phase 1 trial to determine the MTD of ceritinib in adult patients with tumors harboring a genetic alteration in ALK. Secondary objectives were to characterize the safety and side-effect profile, pharmacokinetic profile, and antitumor activity of ceritinib.

HER2 status. Logistic and ordinal regression analyses in addition to likelihood ratio test were used to explore

EGFR inhibition- Overexpression of EGFR is common in patients with TNBC and is seen in up to 60% of basallike breast cancers. It is associated with lower response to chemotherapy and poor overall survival (Nielsen, et al. 2004) the role of EGFR immunostaining in defining basal-like breast cancer, it follows that agents antagonizing this moiety have been assessed in the setting of TNBC. As stated BL-2 and MSL subtypes of TNBC have been found to have higher expression of EGFR pathway genes. Trials have not targeted these specific subtypes with EGF R inhibition, and results have been disappointing in several published abstracts(Carey, et

Cancer is the uncontrollable division and growth of abnormal cells resulting in formation of an aggressive tumour. In some forms of Breast cancer, the cells proliferate uncontrollably due to over-expression of the protein HER2 (Human Epidermal Growth Factor Receptor 2); a receptor embedded within the membrane of cells, allowing for the transfer of signals outside to inside the cell. Trastuzumab is a monoclonal antibody administered through intravenous infusion, to be taken on its own or in combination with one or more chemotherapy regimens. It reduces risk of the cancer reoccurring or spreading by inhibiting the effects of HER2, and enhancing the body’s immune system.

Breast cancer cells have receptors on their surface and in their cytoplasm and nucleus. Chemical messengers such as hormones bind to receptors, and this causes changes in the cell. Breast cancer cells may or may not have

The first generation of CDK inhibitors did not show any evidence of efficacy in clinical trials, but researchers suggest that improved pharmacokinetic and dosing might lead to better results. In addition to that, is crucial to notice that these trials were conducted on unselected patient populations (Musgrove et al., 2011). More selective CDK4/6 inhibitors, such as Palbociclib for advanced-stage oestrogen receptor (ER)+ breast cancer, are now undergoing the final stages of clinical trials and improvements in progression-free survival have been consistently reported (Musgrove et al., 2011; O’Leary et al., 2016).

Through the use of Herceptin and combining it with conventional chemotherapeutic agents, the treatment of the various patients having the metastatic breasts carcinoma can be done effectively. There is an association between the HER2 expression and the Herceptin and that has created new study interests in assessing HER2 expressions in the various breasts tissues accurately.